SKGEL® Implant Versus T-Flux® Implant in the Contralateral Eye in Deep Sclerectomy with Phacoemulsification: Long-Term Follow-Up

Frank Schreyger, Gabor Scharioth, Holger Baatz*
Augenzentrum Recklinghausen, Erlbruch 34-36, D-45657 Recklinghausen, Germany

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 3234
Abstract HTML Views: 2194
PDF Downloads: 764
Total Views/Downloads: 6192
Unique Statistics:

Full-Text HTML Views: 1380
Abstract HTML Views: 1376
PDF Downloads: 502
Total Views/Downloads: 3258

Creative Commons License
2008 Bentham Science Publishers Ltd.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

* Address correspondence to this author at the Augenzentrum Recklinghausen, Erlbruch 34-36, D-45657 Recklinghausen, Germany; E-mail:



To intraindividually compare the efficacy and safety of the SKGEL® implant versus the T-Flux® implant in deep sclerectomy.


In a retrospective analysis 17 patients were identified who underwent combined phacoemulsification-deep sclerectomy and implantation of SKGEL® in one eye and T-Flux® in the contralateral eye.


In eyes with SKGEL® the IOP decreased from 20.6+7.3 mm Hg to 14.8+5.3 mm Hg (-5.8 mm Hg or -28.1%), and in eyes with T-Flux® from 19.9+7.2 mm Hg to 14.7+3.3 mm Hg (-5.2 mm Hg or -26.1%, no statistically significant difference, p >0.05). Antiglaucoma medications with either implant decreased from initially 2.0+0.8 to 0.3+0.7. A qualified success was found in 17/17 eyes with T-Flux® and in 16/17 eyes with SKGEL®. Complete success was achieved in 14/17 eyes with T-Flux® and in 13/17 eyes with SKGEL®.


The IOP-lowering effect and safety of SKGEL® and T-Flux® seem to be comparable.